Skip to content
Longboard Pharmaceuticals Logo
  • About
    • Overview
  • Our Approach
    • Overview
    • Pipeline
    • GPCR Therapies
    • Publications
  • Patients
    • Advocacy & Research Partners
    • Expanded Access Policy
  • Contact
  • About
    • Overview
  • Our Approach
    • Overview
    • Pipeline
    • GPCR Therapies
    • Publications
  • Patients
    • Advocacy & Research Partners
    • Expanded Access Policy
  • Contact
  • About
    • Overview
  • Our Approach
    • Overview
    • Pipeline
    • GPCR Therapies
    • Publications
  • Patients
    • Advocacy & Research Partners
    • Expanded Access Policy
  • Contact

Longboard Pharmaceuticals Announces Initiation of First-in-Human Phase 1 Clinical Study of LP659 in Adult Healthy Volunteers

Home ยป Longboard Pharmaceuticals Announces Initiation of First-in-Human Phase 1 Clinical Study of LP659 in Adult Healthy Volunteers

Longboard Pharmaceuticals Announces Initiation of First-in-Human Phase 1 Clinical Study of LP659 in Adult Healthy Volunteers

Juniper Point2023-12-01T00:56:24+00:0011.29.2023|
  • About
  • Our Approach
  • Patients
  • Contact
[email protected]
(858) 789-9283
4275 Executive Square
Suite 950
La Jolla, CA 92037
Privacy Policy Terms of Use
XLinkedIn
Page load link
Go to Top